Figure 2.
A. Kaplan-Meier analysis of two-year survival for patients with locoregional pancreatic adenocarcinoma, stratified by receipt of EUS. EUS group had improved survival (21.7% vs. 12.8%, p<0.0001).
B. Kaplan-Meier analysis of two year survival for patients with locoregional pancreatic adenocarcinoma and EUS, in patients who underwent surgery. EUS group had improved survival (42.5% vs. 33.4%, p<0.0001).
C. Kaplan-Meier analysis of two year survival for patients with locoregional pancreatic adenocarcinoma and EUS, in patients who did not undergo surgery. EUS group had improved survival (8.6% vs. 5.6%, p<0.0001)